Navigation Links
Kaixin Jieyu Fang for treatment of vascular depression
Date:3/27/2014

The Chinese compound Kaixin Jieyu Fang can be used to treat vascular depression; however, the underlying mechanism remains unclear. Dr. Ying Zhang and co-workers from Guang'anmen Hospital, China Academy of Chinese Medical Sciences in China This study established a rat model of chronic cerebral ischemia-caused white matter damage by ligation of the bilateral common carotid arteries. Rats received daily intragastric administration of a suspension of Kaixin Jieyu Fang powder. Kaixin Jieyu Fang was made from two prescriptions of Kaixin San and Sini San supplemented with Radix Morindae Offcinalis, consisting of eight Chinese herbs including Radix Ginseng, Radix Bupleuri, Fructus Aurantii Immaturus, Radix Morindae Officinalis, Poria, Radix Polygalae, Radix Paeoniae Rubra and Radix Glycytthizae. After treatment, the degree of white matter damage in the cerebral ischemia rat model was alleviated, Bcl-2 protein and mRNA expression in brain tissue increased, and Bax protein and mRNA expression decreased. These results, published in the Neural Regeneration Research (Vol. 9, No. 1, 2014), indicate that Kaixin Jieyu Fang can alleviate cerebral white matter damage, and the underlying mechanism is associated with regulation of Bcl-2/Bax protein and mRNA expression, which is one of possible mechanism behind the protective effect of Kaixin Jieyu Fang against vascular depression.


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related medicine news :

1. Treatment helps reduce risk of esophagus disorder progressing to cancer
2. Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
3. Twenty-five percent of breast cancer survivors report financial decline due to treatment
4. Einstein helps establish $28 million consortium to find ebola treatment
5. Chemo-free treatment a possibility for leukemia/lymphoma
6. Sepsis study comparing 3 treatment methods shows same survival rate
7. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
8. Gene variants protect against relapse after treatment for hepatitis C
9. PSA-testing and early treatment decreases risk of prostate cancer death
10. Emerging multi-drug resistant infections lack standard definition and treatment
11. Making treatment of rare blood disorder more affordable and effective
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Kaixin Jieyu Fang for treatment of vascular depression
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... ... , ... Dr. Richard Amato, a respected periodontist in Monroe, CT, ... Implant Center of Connecticut. As part of the renovation, the cutting-edge practice added two ... to improve patient comfort while making it possible for Dr. Amato to provide even ...
(Date:6/27/2017)... North Hollywood, CA (PRWEB) , ... June 27, ... ... on orthodontic treatments . Orthodontics is a dental specialty that focuses on ... other appliances. Benefits include improved aesthetics and function. , North Hollywood ...
(Date:6/26/2017)... ... June 26, 2017 , ... Torrance dentist, Dr. Robert ... be one of the most noticeable aspects of a person’s appearance. A healthy, radiant ... is born with beautiful, balanced teeth, everyone can have the smile of their dreams ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced ... hiring of Richard Robinson as chief operating officer (COO). In this role, Robinson ... proven track record of simplifying business processes and developing growth strategies to increase ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: